{
    "clinical_study": {
        "@rank": "144590", 
        "arm_group": [
            {
                "arm_group_label": "MHAA4549A Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled, single-ascending dose study w ill assess\n      the safety, tolerability and pharmacokinetics of ascending doses of M HAA4549A in healthy\n      volunteers. Volunteers will be randomized to receive a singl e dose of MHAA4549A or matching\n      placebo."
        }, 
        "brief_title": "A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers\n\n          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive\n\n          -  Weight 40 to 100 kg\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, 12-lead ECG, and vital signs\n\n          -  Clinical laboratory evaluations should be within the reference range for the test\n             laboratory unless deemed not clinically significant by the investigator and Sponsor\n\n          -  Volunteers agree to use acceptable contraceptive measures\n\n        Exclusion Criteria:\n\n          -  History or clinically significant manifestations of disorders\n\n          -  History of anaphylaxis, hypersensitivity or drug allergies\n\n          -  History or presence of an abnormal ECG\n\n          -  History of significant alcohol abuse within 1 year prior to screening or regular use\n             of alcohol within 6 months prior to the screening visit\n\n          -  History of significant drug abuse within 1 year prior to screening\n\n          -  Current tobacco smokers\n\n          -  Positive drug screen at screening or at check-in\n\n          -  Positive pregnancy test result at screening or Day -1 or breast feeding during the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877785", 
            "org_study_id": "GV28916"
        }, 
        "intervention": [
            {
                "arm_group_label": "MHAA4549A Arm", 
                "description": "Single-ascending dose of MHAA4549A", 
                "intervention_name": "MHAA4549A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "description": "Placebo to MHAA4549A", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Quebec", 
                    "country": "Canada", 
                    "zip": "G1P 0A2"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "120 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of anti-therapeutic antibodies", 
                "safety_issue": "No", 
                "time_frame": "120 days"
            }, 
            {
                "measure": "Pharmacokinetics: Serum concentration-time profile of MHAA4549A", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on day 1 to day 120 post-dose"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}